Australia's most trusted
source of pharma news
Tuesday, 10 February 2026
Posted 10 February 2026 AM
As the PBAC March meeting rolls closer it has updated the agenda again, with sponsors asking the Committee to look at the requirements for prescribing their treatments.
Arrotex now has a submission for the PBAC to review the revised proposed price, the restrictions, and the previously estimated utilisation of aZematop in treating atopic dermatitis from its July 2025 recommendation.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.